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Abstract 
Background: In a multicentre, single-arm, observational, phase IV study, we evaluated 24-week treatment adherence 
of relapsing multiple sclerosis (RMS) patients using an electronic auto-injection device (RebiSmart®) for subcutaneous 
injection of interferon (IFN) β-1a.
Methods: A total of 162 adult participants with RMS were enrolled into the study to use RebiSmart® to self-
administer IFN β-1a 44 μg three times weekly for a maximum of 96 weeks. The number of administered injections 
was recorded in the electronic device log. Adherence to treatment was defined as the administration of ≥80 % of 
expected injections. Cognitive impairment and injection anxiety were assessed via questionnaires.
Results: Overall, 91.8 and 82.9 % of participants were adherent to treatment at weeks 12 and 24, respectively. By 
weeks 12 and 24, 8.2 and 13.9 % of participants had discontinued treatment. There were no statistically significant dif-
ferences in adherence rates at weeks 12 and 24 according to cognitive impairment status or injection anxiety. By week 
24, 69.9 % of participants were less fearful of injection than when they started the study. According to participant 
evaluations, the absence of a visible needle, comfort settings, and the calendar for tracking the injection schedule 
were all important features of the RebiSmart® injection system. At week 24, 99.3 % of participants reported that they 
would like to continue using RebiSmart® as their injector.
Conclusions: RebiSmart® use is associated with high treatment adherence, as objectively assessed using electronic 
injection logs. Future research should examine if RebiSmart® use improves long-term treatment outcomes in RMS.
This study was registered with ClinicalTrials.gov as NCT01128075, on May 20, 2010.
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Background
Multiple sclerosis (MS), a chronic inflammatory degener-
ative autoimmune disorder of the central nervous system, 
affects approximately 240 out of every 100,000 Canadians 
[1]. Relapsing forms of MS (RMS), including relapsing-
remitting MS and secondary progressive MS, account 
for approximately 80  % of MS cases and are character-
ized by progressive disability accrued through repeated 
disease relapses [2, 3]. Although MS remains incurable, 
it can be effectively managed via proper treatment with 
disease-modifying drugs (DMDs) such as β-interferons 
[3]. When started early in the course of disease and main-
tained continuously, DMD treatment can reduce relapse 
frequency, slow disability progression, and improve long-
term prognosis [4, 5].
Unfortunately, patient adherence to treatments for MS 
can be inconsistent, leading to poor treatment response 
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and suboptimal long-term patient outcomes. Adher-
ence to medication is the extent to which patients take 
medications as prescribed by their health-care provider 
[6, 7]. While there is no consensus on an acceptable rate 
of adherence, studies in MS have defined 80 % as a gen-
eral threshold for maintaining treatment effectiveness 
[8]. Recent estimates suggest that 25–39 % of MS patients 
miss at least one injection within a 4-week period [9, 10], 
and only 52.2–62.3 % of MS patients are ≥80 % adherent 
to their injectable treatment over a 12–36-month period 
[8, 11]. In addition to intermittently missing treatment 
doses, a significant proportion of patients prematurely 
discontinue treatment within the first year. A recent 
Canadian report indicated cumulative discontinuation 
rates between 20.9 and 26.4  % at 6  months, 36.9 and 
40.9 % at 1 year, and between 52.6 and 58.5 % at 2 years 
among a cohort of adult MS patients in Ontario [12]. 
Many patients who discontinue their initial treatment 
never reinitiate therapy [13]. Several studies have estab-
lished that intermittently missed dosing and treatment 
interruptions are associated with significantly increased 
risks of disease relapse, hospitalization [5, 11], reduced 
quality of life [9], and increased health-care costs [11].
MS patients may experience barriers to treatment 
adherence that include forgetfulness (reported by 50.2 % 
of non-adherent patients) and injection-related issues 
(32 %) such as injection anxiety, injection pain, injection 
fatigue, and skin reactions [9]. Fatigue, flu-like symptoms, 
and headache have been reported by 10–15 % of patients 
as additional reasons for non-adherence [9]. These chal-
lenges may also play a role in treatment discontinuation. 
For instance, a poor injection experience, characterized 
by injection anxiety, injection pain, injection fatigue, or 
injection-site reactions, can lead to premature treatment 
discontinuation [14, 15].
Symptoms of MS may present additional barriers to 
treatment adherence. For example, cognitive impairment 
affects 40–65 % of MS patients, sometimes presenting at 
the earliest stages of the disease [16]. Cognitive impair-
ment can include deficits in several cognitive domains, 
including memory, and may impact patients’ ability to 
remain adherent to their medication [17]. Adherent 
patients have been found to have less neuropsychological 
impairment, as measured by the Multiple Sclerosis Neu-
ropsychological Screening Questionnaire, compared to 
non-adherent patients [9].
RebiSmart®, an electronic, hand-held, multidose, auto-
injection device for IFN-β-1a (Rebif®), was designed 
to address the psychological and physical barriers to 
injection, thereby helping patients adhere to treatment 
[18]. RebiSmart® uses a multidose cartridge that con-
tains three doses of 44  µg IFN-β-1a and can be stored 
at room temperature for 4 weeks [19], making injection 
preparation much simpler. The injection experience is 
improved by incorporating a needle that is never vis-
ible to the patient and customizable injections settings, 
such as needle speed, injection speed, injection time, 
and needle depth. RebiSmart® incorporates an electronic 
dosing log and an alarm that reminds patients of previ-
ous and upcoming injections, respectively. The dosing 
log captures completed, partial, and missed injections, 
allowing patients to see their adherence to treatment 
over the previous 4  weeks. The entire injection log can 
be uploaded to a computer, enabling physicians to objec-
tively monitor adherence. Current research indicates 
that health-care professionals [20] and patients [21] rou-
tinely overestimate adherence to treatment. An objective 
method of measuring treatment adherence would help 
clinicians determine whether breakthrough disease in a 
given patient is due to ineffective treatment or treatment 
non-adherence.
The suitability of the RebiSmart® device for self-injec-
tion was evaluated in RMS patients in a phase IIIb study 
[22]. At week 12, 71.6 % of patients considered the device 
“very suitable” or “suitable” for injection. The majority of 
patients rated “overall convenience” as the most impor-
tant benefit of RebiSmart®. The objective of the current 
study was to evaluate 24-week treatment adherence 
in treatment-naive participants with RMS using Rebi-
Smart®. We assessed whether features of the device were 




MEASURE is a multicentre, single-arm, observational, 
96-week, phase IV study to evaluate treatment adherence 
when using RebiSmart® for self-injection of subcutane-
ous (sc) IFN-β-1a in multidose cartridges in participants 
with relapsing multiple sclerosis (NCT01128075). The 
primary endpoint was evaluated when all participants 
had either completed 24  weeks of treatment or discon-
tinued MEASURE prior to 24  weeks. Data at 48 and 
96 weeks will be reported at a later date.
Participants were evaluated for study eligibility dur-
ing a screening period of up to 28 days. After enrolment, 
each participant attended a clinic visit on study day 1 
(SD1) to complete baseline assessments, receive training 
on RebiSmart®, and administer his or her first injection 
under the supervision of the RebiSmart® trainer. Partici-
pants returned to the clinic for assessments at weeks 12 
and 24 and were evaluated by telephone contact at weeks 
4, 8 and 16.
Participants were provided with a RebiSmart® injector 
for the duration of the study and were trained by a nurse 
on proper use of the device and on standard practice 
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for rotating injection sites. Participants followed the 
IFN β-1a dose titration schedule presented in the Cana-
dian Product Monograph: 8.8 μg tiw during weeks 1–2, 
22 μg in weeks 3–4, and 44 μg tiw from week 5 onward 
[19]. Participants who could not tolerate the 44 μg dose 
following the titration period had their dose reduced to 
22 μg tiw at the discretion of the treating physician. Pro-
phylactic non-steroidal anti-inflammatory drugs could 
be used for the treatment of flu-like symptoms. Partici-
pants could withdraw from the study at any time. Upon a 
patient’s withdrawal, all assessments required at the early 
termination (ET) visit were completed at the earliest time 
possible.
Study objectives and endpoints
The primary objective of this study was to evaluate treat-
ment adherence over 24  weeks when using RebiSmart® 
for self-injection of Rebif® in a multidose cartridge. The 
primary endpoint was the proportion of participants 
at week 24 who were adherent to treatment, defined 
as having administered  ≥80  % of scheduled injections 
as recorded in the RebiSmart® injection log. A cut-off 
of ≥80 % was used to define adherence consistently with 
most clinical trials [7]. Additionally, this level of adher-
ence appears to correlate with reduced risk of severe 
relapse [5]. Treatment adherence over 24  weeks was 
calculated as 100  ×  the number of administered injec-
tions recorded in the electronic device log, divided by the 
expected number of injections (72). Participants who dis-
continued treatment before week 24 were included in the 
analyses of 24-week adherence, with all injections sched-
uled after discontinuation considered missed injections.
Secondary outcome measures also assessed at 24 weeks 
included treatment persistence, treatment compliance, 
treatment adherence among cognitively impaired and 
non-impaired participants, longitudinal changes in injec-
tion anxiety, and qualitative participant experiences with 
RebiSmart®. Treatment persistence was calculated as 
the proportion of participants who remained on treat-
ment at 24  weeks following SD1. Treatment compli-
ance at 24 weeks was calculated as 100 × the number of 
administered injections recorded in the electronic device 
log, divided by (the number of days on-study) × 3/7. It is 
important to note that the calculation of 24-week treat-
ment adherence accounts for doses missed before and 
after treatment discontinuation (up to week 24), and the 
calculation of treatment compliance accounts only for 
those doses missed before treatment discontinuation, for 
those patients who discontinued treatment prior to week 
24. To determine whether impaired cognitive function 
was associated with poorer adherence, 24-week adher-
ence was compared between cognitively impaired and 
non-impaired participants. The change in anxiety was 
evaluated by comparing baseline anxiety scores of the 
hospital anxiety and depression (HAD) scale and the 
state–trait anxiety inventory (STAI) to those at weeks 4, 
8, 12, 16, and 24. Qualitative participant experience with 
RebiSmart® was evaluated by assessing the change in 
score of individual questions as well as defined groups of 
questions in the patient experience questionnaire (PEQ) 
at weeks 4, 8, 12, 16, and 24.
Participants
Adult (18–65  years old) participants with a confirmed 
diagnosis of RMS according to the 2005 McDonald crite-
ria [23] were recruited from 19 community and academic 
centres across Canada to participate in MEASURE. Eth-
ics approval was obtained from the institutional review 
boards at the University of British Columbia (Vancouver, 
BC) and at each of the other participating centers. Partic-
ipants were eligible to enrol if they had been prescribed 
sc IFN β-1a 44  μg tiw according to the Canadian Prod-
uct Monograph, were registered with the Rebif® Mul-
tiple Support Program, and had given written informed 
consent prior to the study screening period. Participants 
were excluded from the study if they had (1) been treated 
with any DMD prior to study enrolment, (2) received any 
other injectable medication on a regular basis in the week 
prior to screening and/or during the study, (3) experi-
enced a relapse within 30 days of screening, or (4) a visual 
or physical impairment that interfered with their ability 
to self-inject using RebiSmart®.
Data collection and analyses
The schedule of assessments until week 24 is summa-
rized in Fig. 1. During the screening period, demographic 
data and medical history (including history of MS) were 
collected. A neurological examination and review of the 
inclusion/exclusion criteria were also completed. A neu-
rological examination including expanded disability sta-
tus scale (EDSS) score was completed again at week 24.
Baseline cognitive function was assessed on SD1 using 
the following four tests from the short form of Rao’s brief 
repeatable battery (BRB): symbol digit modalities test 
(SDMT), the selective reminding test (SRT)-Long-Term 
Storage, the SRT-Consistent Long-Term Retrieval, and 
the 3-second paced auditory serial addition test (PASAT). 
These four tests have been previously identified as the 
most sensitive for detecting cognitive impairment among 
MS patients [24]. Participants were matched to a norma-
tive sample from the Multiple Sclerosis Research Unit at 
Sunnybrook Health Sciences Centre, using the following 
variables: age in years, total number of years of education, 
and sex. The test results from the normative sample were 
used to create cut-off values for each of the four tests. A 
failure for each test was defined as the mean minus 1.5 
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times the standard deviation. Participants were consid-
ered cognitively impaired if they failed two or more of the 
four tests.
Anxiety was assessed on SD1 and at weeks 12 and 24 
using the HAD scale and the STAI. The STAI measures 
temporary, situational anxiety (i.e., state anxiety) and 
daily, non-situational anxiety (i.e., trait anxiety) [25]. The 
STAI was administered immediately before injection 
to get an accurate assessment of the state anxiety asso-
ciated with injection. The HAD scale is a 14-item scale 
that determines the level of anxiety and depression expe-
rienced by a patient. The total score for the HAD scale 
anxiety subscale (HADS-A) can range from 0 to 21. We 
categorized the scores as 0–7 for normal or no anxiety, 
8–10 for mild anxiety, 11–14 for moderate anxiety, and 
15–21 for severe anxiety. The state and trait subscales of 
the STAI produce a range of scores between 20 and 80; a 
higher score indicates greater anxiety. As part of the PEQ, 
participants were asked to rate their fear of self-injection 
on SD1 and at weeks 4, 8, 12, 16, and 24. Fear of injection 
was rated on a scale of 1–5, as follows: not fearful (1), a 
little (2), moderately (3), a lot (4), and a great deal (5).
The PEQ is a 16-item instrument evaluating both the 
participant’s experience with RebiSmart® and side effects 
associated with the administration of Rebif®. The PEQ 
consists of eight questions selected from the Multiple 
Sclerosis Treatment Concern Questionnaire (MSTCQ) 
(four pertaining to injection-site reactions and four 
regarding flu-like symptoms) [22] plus eight questions 
pertaining to the use of RebiSmart®. The full PEQ was 
administered at weeks 4, 8, 12, 16, and 24. Paired change 
was evaluated for each individual who responded to a 
PEQ item at week 4 and a later time point (week 12 or 
24).
Analysis populations
The intent-to-treat (ITT) population comprised 162 
participants who were enrolled in the study and had 
provided written informed consent. The modified ITT 
population (mITT; n  =  158), which comprised all ITT 
participants who received at least one IFN  β-1a injec-
tion recorded by the RebiSmart® device, was used for all 
analyses.
Statistical analysis
No hypothesis testing was conducted. A total of at least 
139 participants were required to provide a 95 % confi-
dence interval (CI) equal to the sample proportion with 
5 % precision, based on the hypothesis that 90 % of par-
ticipants using the auto-injection device for 24  weeks 
would administer 80  % of the scheduled injections. The 
95 % CIs were based on the Agresti–Coull for binomial 
proportions.
The analytical approach for all endpoints was descrip-
tive in nature. No corrections were made for multiple 
comparisons because the comparisons were intended 
Fig. 1 Schedule of study assessments. Asterisk assessments at weeks 4, 8, and 16 were done by telephone contact. The current report focuses on 
data up to week 24 of treatment. BRB brief repeatable battery, HAD hospital anxiety and depression scale, SD1 study day 1, STAI state–trait anxiety 
inventory
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to be hypothesis-generating. Nominal p values are pre-
sented. Changes from baseline in anxiety measures were 
analyzed using a two-sided, paired t test or a Wilcoxon 
matched-pairs signed-rank test. Fisher’s exact test (two-
sided) was used to compare ≥80 % treatment adherence 
(yes/no) rates, while the Mann–Whitney U test (two-
sided) was used to compare mean treatment adherence 
between impaired versus non-impaired participants as 
well as between participants with fear versus no fear of 
injection. Statistical analyses were performed using the 
SAS System for Windows, Version 9.2 (Cary, NC).
In addition, a post hoc logistic regression analysis was 
undertaken to identify potential associations in the mITT 
population between patient baseline characteristics (gen-
der, cognitive impairment, PASAT, age, education level, 
months since MS diagnosis, months since MS symptoms, 
months since last relapse, EDSS, HADS-D, HADS-A, and 
STAI state and trait anxiety scores) and ≥80 % treatment 
adherence at week 24. Continuous variables were dichot-
omized as less than versus greater than or equal to the 
population median value.
Results
The baseline demographic and disease characteristics 
of the 162 participants included in the ITT popula-
tion are listed in Table 1. Participants had a mean ± SD 
age of 37.4 ±  9.8  years and were predominantly female 
(75.3  %) and Caucasian (94.4  %). Nearly all participants 
(96.3 %) had RMS; the majority of participants (82.1 %) 
had experienced between 1 and 3 relapses since the onset 
of MS symptoms, and the mean EDSS score of the study 
sample was 1.8 ± 1.3. Baseline results of the four cogni-
tive tests constituting a short form of Rao’s BRB showed 
that 47.8 % of participants failed two or more of the four 
tests and, by our definition, were classified as cognitively 
impaired.
Treatment adherence and compliance rates at weeks 12 
and 24 for all participants with at least one injection using 
the RebiSmart® injector (mITT; n =  158) are shown in 
Fig. 2. The proportion of participants with ≥80 % adher-
ence to treatment was 91.8  % (95  % CI 86.3, 95.2  %) at 
week 12 and 82.9  % (95  % CI 76.2, 88.0  %) at week 24. 
The proportion of participants with  ≥80  % compli-
ance to treatment was 95.6  % (95  % CI 91.0, 98.0  %) at 
week 12 and 92.4  % (95  % CI 87.1, 95.7  %) at week 24. 
The mean  ±  SD adherence rate of all participants was 
95.7 ± 11.6 % at week 12 and 89.1 ± 20.3 % at week 24. 
The mean  ±  SD compliance rate of participants was 
97.6 ± 6.9 % at week 12 and 95.2 ± 9.7 at week 24. Only 
13 (8.2  %) participants discontinued treatment by the 
12th week; by week 24 this number rose to 22 (13.9  %) 
participants. The reasons for treatment discontinuation 
at weeks 12 and 24 included participant withdrawal of 
consent (4 [30.8  %] and 7 [31.8  %], respectively), inves-
tigator decision (2 [15.4 %] and 4 [18.2 %], respectively) 
and other (6 [46.2 %] and 9 [40.95], respectively).
Our data (Fig.  3) show that a similar proportion of 
cognitively impaired and unimpaired participants 
achieved ≥80 % adherence to treatment at week 12 (88.1 % 
Table 1 Baseline demographic and disease characteristics 
of ITT patient population
Data presented as mean ± standard deviation except as indicated
ITT intent-to-treat, MS multiple sclerosis
Characteristic Result (n = 162)
Demographics
 Age, years 37.4 ± 9.8
Sex
 Male, n (%) 40 (24.7 %)
 Female, n (%) 122 (75.3 %)
Race
 Caucasian, n (%) 153 (94.4 %)
 Black, n (%) 2 (1.2 %)
 Asian, n (%) 2 (1.2 %)
 Other, n (%) 5 (3.1 %)
 Education, total years completed 14.9 ± 3.3
Disease characteristics
 MS classification
  Relapsing-remitting, n (%) 156 (96.3 %)
  Secondary progressive, n (%) 6 (3.7 %)
  Months since onset of MS symptoms 53.3 ± 76.1
  Months since MS diagnosis 24.0 ± 57.6
  Months since last relapse 6.4 ± 9.5
Number of relapses since onset of MS symptoms, n (%)
 0 6 (3.7 %)
 1 44 (27.2 %)
 2 55 (34.0 %)
 3 34 (21.0 %)
 4 12 (7.4 %)
 ≥5 11 (6.8 %)
 Expanded disability status scale (EDSS) Score 1.8 ± 1.3
Cognitive function
 Symbol digit modalities test (SDMT) 51.0 ± 13.1
 Patients failing test, n (%) 35 (22.9 %)
Selective reminding test (SRT)
 Long-term storage 41.8 ± 15.5
 Patients failing test, n (%) 61 (40.4 %)
 Consistent long-term retrieval 30.0 ± 15.8
 Patients failing test, n (%) 59 (39.1 %)
3-second paced auditory serial addition test (PASAT) 42.8 ± 11.4
 Patients failing test, n (%) 47 (31.3 %)
Cognitively impaired (failing ≥2 of the above tests) 67 (47.8 %)
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and 94.5 %, respectively; p = 0.23) and week 24 (80.6 and 
83.6 %, respectively; p = 0.67). Similarly, there was no dif-
ference in mean adherence rates at week 12 (94.3 ± 14.3 
and 96.8  ±  8.7  %, respectively; p  =  0.651) and week 24 
(86.6 ± 22.9 and 90.4 ± 18.6 %, respectively; p = 0.23) for 






























Adherence ≥ 80% Compliance ≥ 80% 
Fig. 2 Proportion of participants with ≥80 % treatment adherence and compliance at week 12 and 24 (mITT population). Adherence calculated as 
100 × the number of administered injections recorded in the electronic device log divided by the expected number of injections (e.g., 72 injections 
over 24 weeks). Compliance calculated as 100 times the number of injections recorded in the electronic device log divided by (the number of days 
on-study) × 3/7. mITT modified intent-to-treat
Fig. 3 Proportion of participants with ≥80 % treatment adherence according to cognitive impairment at weeks 12 and 24 (mITT population). p 
value assessed via Fisher’s exact test. mITT modified intent-to-treat
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The change in ratings of fear of injection at base-
line, week 12, and week 24 are illustrated in Fig.  4. The 
proportion of participants reporting “moderate,” “a 
lot,” or “a great deal” of injection fear at baseline was 
48.3  %; this number declined to 18.7  % at week 12 and 
16.0  % at week 24. Indeed, by week 24, 69.9  % of par-
ticipants became less fearful of injection than they had 
been at SD1. Mean ± SD pre-injection state anxiety also 
declined significantly, from SD1 (40.4  ±  12.3) to week 
12 (35.9 ±  12.7; p  <  0.0001) and week 24 (36.6 ±  12.9; 
p  <  0.0001). As illustrated in Fig.  5, similar proportions 
of participants with and without fear of injection at base-
line achieved ≥80 % adherence to treatment at week 12 
(91.4  % vs. 92.1  %, respectively; p =  1.00) and week 24 
(81.5 vs. 84.2 %, respectively; p = 0.68). Mean adherence 
rates were also similar between participants with versus 
those without baseline fear of injection at week 12 (96.1 
vs. 95.2 %, respectively; p = 0.322) and week 24 (89.0 vs. 
89.0  %, respectively; p =  0.901). Indeed, logistic regres-
sion querying various patient baseline characteristics 
identified no significant associations between adher-
ence and patient gender, age, education, cognitive func-
tion, disease history, severity of impairment, anxiety or 
depression (data not shown).
As listed in Table  2, mean  ±  SD general anxiety, as 
assessed by the anxiety subscale score of the HAD scale, 
was significantly lower at weeks 12 and 24 by compari-
son to baseline (5.8  ±  4.3 and 5.9  ±  4.1 vs. 7.0  ±  4.1, 
respectively; p < 0.0001 for both). Likewise, mean ± SD 
trait anxiety was also significantly reduced from baseline 
to week 12 (38.8  ±  10.9 and 36.7  ±  12.1, respectively; 
p = 0.002).
Injection-site reactions (questions 2–5) and flu-like 
symptoms (questions 10–13) were measured using ques-
tions from the MSTCQ at weeks 4, 12, and 24 and are 
reported in Table 3. The flu-like symptom score declined 
from a mean score of 11.1 at week 4 to 10.1 at week 24, 
and the injection-site reaction score increased from 11.2 
at week 4 to 12.4 at week 24.
Patients’ experience and use of other features of Reb-
iSmart® was evaluated by additional questions within 
the PEQ. The proportion of participants reporting 
no pain or mild pain (PEQ question 6) was 53.2  % at 
week 4, 52.7 % at week 12, and 49.6 % at week 24/early 
termination. By week 24 or early termination, 63.3  % 
of participants reported (PEQ question 8) changing 
the comfort settings on RebiSmart®. Of the 42.1  % of 
participants who had changed the comfort settings by 
week 4, 50 % reported “a little” improvement in injec-
tion experience, 20.3 % reported “moderate” improve-
ment, and 10.9  % reported “a lot” or “a great deal” of 
improvement. The majority of participants (63.2  %) 
reported using the device’s injection calendar (PEQ 
question 9) at week 4 (“a little” [28.3 %], “moderately” 
[17.1 %], “a lot” [11.2 %], and “a great deal” [6.6 %]); by 
week 24, 46.7  % of participants continued using this 
feature. At week 24, nearly all participants (99.3  %) 
reported that they would like to continue using 
Fig. 4 Participant self-reported fear of injection at baseline, week 12, and week 24 (mITT population). Based on patient response to the following 
question: “Please rate your current fear of self-injection.” mITT modified intent-to-treat
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RebiSmart® as their injector (PEQ question 16). The 
absence of a visible needle was reported by partici-
pants as the most important feature of the RebiSmart® 
injection device (66.2 %; PEQ question 14), followed by 
the injection comfort settings for improving injection 
experience (27.1  %), and lastly the injection calendar 
for tracking injection administration (6.8  %). Figure  6 
shows that 52  % of participants reported the amount 
of time and preparation of their injection with Rebi-
Smart® was “not at all bothersome” at SD1. That pro-
portion increased to 64.4 % by week 12 and 71.5 % by 
week 24 or early termination.
Discussion
RebiSmart® was specifically designed with features 
to assist patients in maintaining good adherence to 
Fig. 5 Proportion of participants with ≥80 % treatment adherence according to fear of injection at weeks 12 and 24 (mITT population). p value 
assessed via Fisher’s exact test. mITT modified intent-to-treat
Table 2 Change in  anxiety during  treatment (mITT popu-
lation)
* p < 0.005 by comparison to baseline, as calculated by a paired t-test
mITT modified intent-to-treat
Measure Baseline Week 12 Week 24
Hospital anxiety and depression scale
 Anxiety subscale score
(range 0–21)
7.0 ± 4.1 5.8 ± 4.3* 5.9 ± 4.1*
State–trait anxiety inventory
 State anxiety subscale
(range 20–80)
40.4 ± 12.3 35.9 ± 12.7* 36.6 ± 12.9*
 Trait anxiety subscale
(range 20–80)
38.8 ± 10.9 36.7 ± 12.1* 37.6 ± 12.1
Table 3 Multiple Sclerosis Treatment Concern Question-
naire score for  subscales relating to  injection-site reac-




Observed Paired  
change
Observed Paired  
change
Week 4
 N (missing) 152 (5) – 152 (2) –
 Mean (SD) 11.2 (3.6) – 11.1 (4.6) –
 Median 
(range)
12 (1–20) – 12 (1–20) –
Week 12
 N (missing) 149 (2) 144 (7) 148 (3) 143 (8)
 Mean (SD) 12.3 (3.0) 1.1 (2.8) 10.8 (4.2) –0.2 (4.3)
 Median 
(range)
13 (4–20) 1 (−6 to +12) 11 (1–20) 0 (–12 to +17)
Week 24
 N (missing) 137 (1) 133 (5) 137 (1) 133 (5)
 Mean (SD) 12.4 (3.0) 1.3 (3.1) 10.1 (4.3) –0.8 (4.1)
 Median 
(range)
13 (1–18) 1 (−8 to +14) 10 (1–20) –1 (–3 to +1)
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treatment so they can realize the full benefits of ther-
apy. The primary objective of the MEASURE study was 
to evaluate treatment adherence of RMS participants 
using RebiSmart® for self-injection of sc IFN β-1a at 
24 weeks. Our results show that the majority of partici-
pants achieved  ≥80  % adherence with RebiSmart® and 
exhibited compliance and discontinuation rates that are 
superior to other methods of injection for DMDs and 
very similar to oral DMDs [9, 10, 26]. Additionally, our 
findings revealed a high level of participant acceptance of 
the RebiSmart® device.
As objectively recorded by the RebiSmart® dosing log 
at weeks 12 and 24, 91.8  % (95  % CI 86.3, 95.2  %) and 
82.9 % (95 % CI 76.2, 88.0 %) of RMS participants, respec-
tively, achieved good adherence, as defined by adminis-
tration of  ≥80  % of the planned doses. Our adherence 
data are in agreement with the 12-week, open-label 
BRIDGE study, which included 119 Italian RMS patients 
using RebiSmart® for self-injection of sc IFN β-1a [27]. 
In that trial, 88.2 % of patients achieved good treatment 
adherence over a 12-week period; medical reasons and 
forgetfulness were the main causes of missed doses. This 
level of adherence compares favourably with the esti-
mated 61–75  % of MS patients who self-report being 
adherent to traditional injectable DMD therapy [9, 10], 
as well as the 58.5–62.3 % of MS patients who regularly 
refill their prescriptions for injectable DMD therapy over 
the long-term [8, 11]. Additionally, the level of adher-
ence with RebiSmart® reported herein is close to that 
reported for oral medication use among patients with 
other chronic diseases (93.0 %) [26].
The proportion of participants with ≥80 % compliance 
to treatment was 95.6 % at week 12 and 92.4 % at week 
24; these rates also compare favourably with compli-
ance ≥80 % at week 12 among 96.3 % of patients in the 
BRIDGE study. Furthermore, only 13.9 % of participants 
had discontinued treatment with RebiSmart® by week 
24, by comparison to an estimated 20.9–26.4  % of MS 
patients who discontinue DMD therapy within 6 months 
of treatment initiation [12]. Based on comparisons with 
available literature, MS treatment with RebiSmart® 
appears to produce superior adherence and persistence 
rates relative to other injection methods.
Several features of RebiSmart® may contribute to the 
high level of treatment adherence and compliance doc-
umented in this study. Approximately half of partici-
pants (48.4 %) reported some degree of fear of injection 
at baseline, a known risk factor for poor adherence [9, 
28]. In order to overcome this common treatment bar-
rier, the RebiSmart® auto-injector employs a concealed 
needle that cannot be seen by patients before or after 
the injection. Additionally, in order to reduce poten-
tial injection-site pain, the device includes an adjustable 




































1 Not at all bothersome 2 3 4 5 Very bothersome 
Fig. 6 Patient self-reported degree of “bother” associated with RebiSmart® use (mITT population) Based on patient response to the following ques-
tion: “How bothersome was the amount of time and preparation it took to get everything ready for your Rebif® injection with RebiSmart®?”
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needle speed, injection speed, depth, and duration. Par-
ticipants in the current trial identified the absence of a 
visible needle as the most important benefit of the Rebi-
Smart® auto-injector, followed by the comfort settings 
for improving injection experience. By weeks 12 and 24, 
two-thirds (66.9 and 69.9  %, respectively) of RMS par-
ticipants became less fearful of injection than they had 
been at baseline. Additionally, participants’ baseline anxi-
ety level prior to injection was also reduced by weeks 12 
and 24 of treatment (from 40.4 ± 12.3 to 35.9 ± 12.7 and 
36.6 ± 12.9, respectively). Interestingly, treatment adher-
ence at weeks 12 and 24 was equally high among partici-
pants who had expressed anxiety at baseline compared 
with those who had not (96.1 vs. 95.2 % at week 12 and 
89.0 vs. 89.0 % at week 24). Our data suggest the hidden 
needle and injection comfort settings may contribute to 
reducing injection fear and anxiety and maintaining good 
adherence and compliance.
MS affects several aspects of cognitive function includ-
ing processing speed, executive function, and memory 
[16, 29]. Here, 47.6 % of RMS patients had some degree 
of cognitive dysfunction at baseline. The proportion of 
participants with cognitive dysfunction in our sample 
is in general agreement with previously reported esti-
mates in this population (40–65 %) [16]. Forgetfulness, a 
dimension of cognitive impairment, has been previously 
identified as a major reason for poor adherence to MS 
therapy [9]. The injection calendar and an optional injec-
tion reminder alarm are RebiSmart® features designed to 
overcome forgetfulness. We did not observe an influence 
of cognitive impairment on treatment adherence. Cog-
nitively impaired and non-impaired RMS participants 
achieved similar rates of mean adherence to sc IFN β-1a 
administered with RebiSmart® at weeks 12 (94.3 ± 14.3 
and 96.8 ± 8.7 %, respectively) and 24 (86.6 ± 22.9 and 
90.4 ± 18.6 %, respectively). This finding agrees with the 
BRIDGE study, which reported no association between 
cognitive function, as assessed by PASAT score, and 
adherence to RebiSmart® sc IFN β-1a treatment at 
12  weeks [27]. These findings suggest features of Rebi-
Smart® may help participants overcome the barrier of 
cognitive impairment and achieve good adherence and 
compliance.
Objective adherence monitoring using RebiSmart® 
may also contribute to improved treatment adherence for 
participants. While self-report is a convenient method 
for ascertaining treatment adherence, MS participants 
tend to overestimate their level of adherence [30]. Thus, 
treatment failure due to poor adherence may be misin-
terpreted by physicians as a lack of treatment efficacy, 
leading to unnecessary dose escalation or treatment 
change. RebiSmart® is the first injection device used in 
MS that provides an accurate record of dosing history. 
While the dosing history log was rated by participants 
in an earlier study as the least useful feature of the Rebi-
Smart® device [31], this function can be of great utility 
to physicians. The log, which can be readily downloaded 
onto the physician’s computer, provides an up-to-date, 
objective measure of a participant’s treatment adherence, 
thereby overcoming the limitations inherent in patient 
self-report.
Our findings also revealed a high level of acceptance of 
the device, with almost all participants (99.3  %) report-
ing at 24  weeks that they would like to continue using 
RebiSmart® as their injector. This observation agrees 
with prior patient rating studies that showed RebiSmart® 
is generally well-accepted by RMS patients [22, 31]. For 
instance, a prior multicentre, open-label, observational, 
phase IV study in the UK and Ireland observed that 92 % 
of RMS patients liked using the device. Convenience and 
ease of use have been frequently reported by RMS partic-
ipants as the major benefits of RebiSmart® [22, 31]. In the 
current study, 71.5 % of participants indicated that injec-
tion with RebiSmart® was convenient.
The current study has a number of limitations. As the 
MEASURE study lacked a control or active comparator 
group, it is not possible to generalize the current findings 
beyond the population of patients receiving sc IFN β-1a 
via the RebiSmart® injection system. In addition, since p 
values in our exploratory analyses were not corrected for 
multiple comparisons, the statistical significance of our 
secondary outcomes should be interpreted with caution. 
Finally, while 24 weeks of follow-up currently represents 
the longest report of treatment adherence, longer-term 
follow-up data from the MEASURE study, extending to 
96 weeks of treatment, is forthcoming.
Conclusions
The RebiSmart® auto-injection device addresses a num-
ber of known barriers to MS treatment adherence and is 
well received by RMS patients. The use of an electronic 
auto-injector for administration of IFN β-1a is associated 
with good treatment adherence at 6 months among four 
in five RMS patients, regardless of cognitive function or 
fear of injection at baseline. Future analyses from this 
trial will determine whether these encouraging adher-
ence rates correspond with a reduction in the frequency 
of relapse and a delay in disability progression.
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